Generation of a monoclonal antibody recognizing mouse PD-1.
暂无分享,去创建一个
[1] D. McDermott,et al. Potential of New Therapies like Anti-PD1 in Kidney Cancer , 2014, Current Treatment Options in Oncology.
[2] G. Freeman,et al. Strength of PD-1 signaling differentially affects T-cell effector functions , 2013, Proceedings of the National Academy of Sciences.
[3] C. Liu,et al. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. , 2010, Cellular and molecular biology.
[4] V. García,et al. Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis1 , 2008, The Journal of Immunology.
[5] Ping Zhang,et al. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. , 2008, Molecular immunology.
[6] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[7] Yoshimasa Tanaka,et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.
[8] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.